NCT06557473

Brief Summary

Hypertension is an important health challenge that affects millions of people across the world today and is a major risk factor for multiple system comorbidities. Intraoperative hypotension may lead to negative outcomes. 'Post-induction hypotension' (PIH; i.e. arterial hypotension defined as hypotension during the first 20 min after anesthesia induction, or from anesthesia induction until the beginning of surgery) and 'early intraoperative hypotension' (eIOH; i.e. arterial hypotension occurring during the first 30 min of surgery). Lidocaine is a local anesthetic drug with multiple systemic uses. Systemic lidocaine used as at the perioperative period has analgesic, and anti-inflammatory properties which make it capable of reducing intra- and postoperative drug consumptions and patients' hospital stay. Therefore, we hypothesize that the use of lidocaine as an adjuvant to propofol might reduce the risk of post induction hypotension and hence having more stable hemodynamic profile during induction of anesthesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at below P25 for phase_4 hypertension

Timeline
Completed

Started Apr 2023

Shorter than P25 for phase_4 hypertension

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2023

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 13, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 16, 2024

Completed
Last Updated

August 23, 2024

Status Verified

August 1, 2024

Enrollment Period

1.1 years

First QC Date

August 13, 2024

Last Update Submit

August 22, 2024

Conditions

Keywords

HypertensionPostinduction hypotensionLidocaineFentanyl

Outcome Measures

Primary Outcomes (1)

  • MAP

    Mean Arterial blood pressure 1 minute after induction of anesthesia.

    1 minute after GA induction

Secondary Outcomes (1)

  • Number of hypotensive episodes

    20 minutes

Study Arms (2)

The lidocaine group

ACTIVE COMPARATOR

Anesthesia will be induced using 1.5 mg/kg lidocaine in the lidocaine group (L), 2mg/kg propofol, and 0.5 mg atracurium.

Drug: Lidocaine IV

The fentanyl group

PLACEBO COMPARATOR

Anesthesia will be induced using 2 µg/kg fentanyl in the fentanyl group (F), 2mg/kg propofol, and 0.5 mg atracurium.

Drug: Fentanyl

Interventions

1.5mg/kg IV for induction of GA

The lidocaine group

Fentanyl IV 2 µg/kg for GA induction

The fentanyl group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • ASA II, Hypertensive patients with the following criteria:
  • Diagnosed with hypertension more than 5 years and on continuous medications.
  • Controlled hypertension (systolic pressure \< 140 mm Hg and the diastolic \< 90 mm Hg).
  • Age: 18-60 years of both sexes.
  • Elective non cardiac surgery requiring general anesthesia.

You may not qualify if:

  • Uncontrolled hypertension (SPB \> 140 mm Hg) OR (DBP \< 90 mm HG).
  • SVV (stroke volume variability) ≥ 13.
  • Patients with suspected difficult intubation as judged by the attending anesthetist during the preoperative assessment and patients for whom an alternative device other than an endotracheal tube will be considered.
  • Pregnancy.
  • History of drug abuse.
  • Obese patients (BMI ≥ 35kg/m2).
  • Allergy to any of the used medications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Theodor Bilharz Research Institute

Giza, Egypt

Location

Related Publications (3)

  • Yancey R. Anesthetic Management of the Hypertensive Patient: Part II. Anesth Prog. 2018 Fall;65(3):206-213. doi: 10.2344/anpr-65-03-17.

    PMID: 30235430BACKGROUND
  • Aissaoui Y, Jozwiak M, Bahi M, Belhadj A, Alaoui H, Qamous Y, Serghini I, Seddiki R. Prediction of post-induction hypotension by point-of-care echocardiography: A prospective observational study. Anaesth Crit Care Pain Med. 2022 Aug;41(4):101090. doi: 10.1016/j.accpm.2022.101090. Epub 2022 May 1.

    PMID: 35508291BACKGROUND
  • Hu AM, Qiu Y, Zhang P, Zhao R, Li ST, Zhang YX, Zheng ZH, Hu BL, Yang YL, Zhang ZJ. Higher versus lower mean arterial pressure target management in older patients having non-cardiothoracic surgery: A prospective randomized controlled trial. J Clin Anesth. 2021 May;69:110150. doi: 10.1016/j.jclinane.2020.110150. Epub 2021 Jan 6.

    PMID: 33418429BACKGROUND

MeSH Terms

Conditions

Hypertension

Interventions

Fentanyl

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

PiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
An investigator not participating in the study was responsible for drug preparation and allocation according the computer generated random numbers.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: comparison of lidocaine and fentanyl in hemodynamic stability after induction of general anesthesia in hypertensive patients.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

August 13, 2024

First Posted

August 16, 2024

Study Start

April 1, 2023

Primary Completion

May 1, 2024

Study Completion

July 1, 2024

Last Updated

August 23, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

data will be available upon request from the principal investigator

Locations